|
US5364858A
(en)
*
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5244903A
(en)
*
|
1987-03-31 |
1993-09-14 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5053512A
(en)
*
|
1987-04-14 |
1991-10-01 |
Research Triangle Institute |
Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
|
|
US5227380A
(en)
*
|
1987-03-31 |
1993-07-13 |
Research Triangle Institute |
Pharmaceutical compositions and methods employing camptothecins
|
|
US4894456A
(en)
*
|
1987-03-31 |
1990-01-16 |
Research Triangle Institute |
Synthesis of camptothecin and analogs thereof
|
|
US5122526A
(en)
*
|
1987-03-31 |
1992-06-16 |
Research Triangle Institute |
Camptothecin and analogs thereof and pharmaceutical compositions and method using them
|
|
US4981968A
(en)
*
|
1987-03-31 |
1991-01-01 |
Research Triangle Institute |
Synthesis of camptothecin and analogs thereof
|
|
US5106742A
(en)
*
|
1987-03-31 |
1992-04-21 |
Wall Monroe E |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5180722A
(en)
*
|
1987-04-14 |
1993-01-19 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
|
|
US5340817A
(en)
*
|
1987-04-14 |
1994-08-23 |
Research Triangle Institute |
Method of treating tumors with anti-tumor effective camptothecin compounds
|
|
US5122606A
(en)
*
|
1987-04-14 |
1992-06-16 |
Research Triangle Institute |
10,11-methylenedioxy camptothecins
|
|
US5049668A
(en)
*
|
1989-09-15 |
1991-09-17 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin analogs
|
|
US4939255A
(en)
*
|
1987-06-24 |
1990-07-03 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic camptothecin derivatives
|
|
US4943579A
(en)
*
|
1987-10-06 |
1990-07-24 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Water soluble prodrugs of camptothecin
|
|
US5004758A
(en)
*
|
1987-12-01 |
1991-04-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
|
|
JPH0615547B2
(ja)
*
|
1988-01-20 |
1994-03-02 |
株式会社ヤクルト本社 |
新規なカンプトテシン誘導体
|
|
US5552154A
(en)
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5225404A
(en)
*
|
1989-11-06 |
1993-07-06 |
New York University |
Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
|
|
US6407115B1
(en)
*
|
1991-01-16 |
2002-06-18 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic compound
|
|
US5658920A
(en)
*
|
1991-01-16 |
1997-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
|
|
WO1993009782A1
(en)
|
1991-11-15 |
1993-05-27 |
Smithkline Beecham Corporation |
Combination chemotherapy
|
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5391745A
(en)
*
|
1992-07-23 |
1995-02-21 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparation of camptothecin analogs
|
|
US5446047A
(en)
*
|
1992-07-23 |
1995-08-29 |
Sloan-Kettering Institute For Cancer Research |
Camptothecin analogues
|
|
AP9300587A0
(en)
*
|
1992-11-12 |
1995-05-05 |
Glaxo Inc |
Water soluble camptothecin derivatives.
|
|
US5447936A
(en)
*
|
1993-12-22 |
1995-09-05 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
|
|
GB9402934D0
(en)
*
|
1994-02-16 |
1994-04-06 |
Erba Carlo Spa |
Camptothecin derivatives and process for their preparation
|
|
US5468754A
(en)
*
|
1994-04-19 |
1995-11-21 |
Bionumerik Pharmaceuticals, Inc. |
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
|
|
US5597829A
(en)
*
|
1994-05-09 |
1997-01-28 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin and methods for uses thereof
|
|
US5604233A
(en)
*
|
1994-04-28 |
1997-02-18 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
|
|
US5646159A
(en)
*
|
1994-07-20 |
1997-07-08 |
Research Triangle Institute |
Water-soluble esters of camptothecin compounds
|
|
US5614529A
(en)
*
|
1994-09-22 |
1997-03-25 |
Research Triangle Institute |
Inhibition of plasmodia parasites by camptothecin compounds
|
|
US5972955A
(en)
*
|
1995-06-06 |
1999-10-26 |
Dr. Reddy's Research Foundation |
Water soluble C-ring analogues of 20(S)-camptothecin
|
|
US6177439B1
(en)
|
1995-06-06 |
2001-01-23 |
Reddy's Research Foundation |
Water soluble analogues of 20(S)-camptothecin
|
|
US6214836B1
(en)
|
1995-06-06 |
2001-04-10 |
Dr. Reddy's Research Foundation |
Water soluble analogues of 20(S)-camptothecin
|
|
US5942386A
(en)
*
|
1995-06-07 |
1999-08-24 |
Thomas Jefferson University |
Anti-fungal agents and methods of identifying and using the same
|
|
WO1997019085A1
(en)
*
|
1995-11-22 |
1997-05-29 |
Research Triangle Institute |
Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
|
|
US6395541B1
(en)
|
1996-05-23 |
2002-05-28 |
The Rockefeller University |
Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
|
|
IL127800A
(en)
*
|
1996-08-19 |
2005-11-20 |
Bionumerik Pharmaceuticals Inc |
Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
|
|
AU746875B2
(en)
*
|
1997-02-27 |
2002-05-02 |
Pharmacia & Upjohn Company |
Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
|
|
JP3046258B2
(ja)
*
|
1997-04-11 |
2000-05-29 |
株式会社ヤクルト本社 |
1−クロロカルボニル−4−ピペリジノピペリジンまたはその塩酸塩の製造方法
|
|
ID23424A
(id)
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
|
US6214821B1
(en)
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
|
NZ509859A
(en)
*
|
1998-08-05 |
2003-09-26 |
Aventis Pharma S |
Use of camptothecin derivatives, with reduced gastrointestinal toxicity
|
|
US6043367A
(en)
*
|
1998-09-30 |
2000-03-28 |
Roffler; Steve |
Proactive antitumor compounds
|
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
US6228855B1
(en)
*
|
1999-08-03 |
2001-05-08 |
The Stehlin Foundation For Cancer Research |
Aromatic esters of camptothecins and methods to treat cancers
|
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6159935A
(en)
|
1999-11-29 |
2000-12-12 |
Pharmacia & Upjohn Co. |
Method for preventing diarrhea
|
|
KR100717916B1
(ko)
|
2000-02-28 |
2007-05-11 |
아방티 파르마 소시에테 아노님 |
캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
|
|
US6545010B2
(en)
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
|
AR027687A1
(es)
*
|
2000-03-22 |
2003-04-09 |
Yakult Honsha Kk |
Procedimiento para preparar camptotecina
|
|
EP1286671B1
(de)
*
|
2000-05-15 |
2006-04-05 |
Celgene Corporation |
Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
|
|
ATE322266T1
(de)
|
2000-05-15 |
2006-04-15 |
Celgene Corp |
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
|
|
US6486320B2
(en)
|
2000-09-15 |
2002-11-26 |
Aventis Pharma S.A. |
Preparation of camptothecin and of its derivatives
|
|
IL155509A0
(en)
|
2000-10-27 |
2003-11-23 |
Aventis Pharma Sa |
A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
|
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
|
PL372318A1
(en)
*
|
2002-03-01 |
2005-07-11 |
Pharmacia Italia S.P.A. |
Crystalline polymorphic form of irinotecan hydrochloride
|
|
CN1649627A
(zh)
*
|
2002-04-26 |
2005-08-03 |
法赫马西亚及普强有限公司 |
用于治疗、预防或延迟肿瘤发生的方法和组合物
|
|
NZ536475A
(en)
*
|
2002-05-24 |
2008-06-30 |
Schering Corp |
Neutralizing human anti-igfr antibody
|
|
CN100363366C
(zh)
*
|
2002-06-27 |
2008-01-23 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及制备方法
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
|
US7151179B2
(en)
|
2003-05-12 |
2006-12-19 |
Scinopharm Taiwan, Ltd. |
Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
|
|
US7067666B2
(en)
*
|
2003-06-27 |
2006-06-27 |
Research Triangle Institute |
7-substituted camptothecin and camptothecin analogs and methods for producing the same
|
|
CZ299329B6
(cs)
*
|
2003-08-26 |
2008-06-18 |
Pliva-Lachema A.S. |
Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
|
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
CZ299593B6
(cs)
*
|
2003-12-16 |
2008-09-10 |
Pliva-Lachema A. S. |
Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
|
|
WO2005062985A2
(en)
*
|
2003-12-23 |
2005-07-14 |
American Bioscience, Inc. |
Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
|
|
CA2556254A1
(en)
*
|
2004-02-13 |
2005-08-25 |
Kabushiki Kaisha Yakult Honsha |
Aqueous solution preparation containing camptothecins
|
|
CN1946421B
(zh)
|
2004-04-27 |
2013-07-17 |
威尔斯达特生物制剂公司 |
使用病毒和喜树碱进行的癌症治疗
|
|
CA2821167C
(en)
|
2004-05-03 |
2016-06-28 |
Merrimack Pharmaceuticals, Inc. |
Drug delivery liposomes containing anionic polyols or anionic sugars
|
|
US20050267141A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives
|
|
CN1960729B
(zh)
|
2004-06-01 |
2012-04-11 |
泰尔茂株式会社 |
伊立替康制剂
|
|
US20050272757A1
(en)
*
|
2004-06-04 |
2005-12-08 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
|
|
CN101052378A
(zh)
|
2004-09-07 |
2007-10-10 |
生物相容英国有限公司 |
从栓塞剂送递药物
|
|
JP4829120B2
(ja)
*
|
2004-10-01 |
2011-12-07 |
株式会社ヤクルト本社 |
イリノテカン酸付加塩
|
|
US7205385B2
(en)
*
|
2004-11-12 |
2007-04-17 |
General Electric Company |
Polymerization method for the synthesis of polypeptide imaging agents
|
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
|
WO2006082053A1
(en)
*
|
2005-02-02 |
2006-08-10 |
Heidelberg Pharma Gmbh |
7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
|
|
ATE446299T1
(de)
*
|
2005-02-07 |
2009-11-15 |
Fermion Oy |
Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
|
|
ES2430375T3
(es)
*
|
2005-02-08 |
2013-11-20 |
Fermion Oy |
Procedimiento para la producción de cloruro de [1,4']bipiperidinil-1'-carbonilo o su clorhidrato
|
|
EP1928883B1
(de)
*
|
2005-02-08 |
2013-10-30 |
Fermion Oy |
Verfahren zur herstellung von irinotecanhydrochlorid
|
|
US20070117784A1
(en)
*
|
2005-03-04 |
2007-05-24 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with anthraquinones
|
|
CN101193644A
(zh)
*
|
2005-03-04 |
2008-06-04 |
诺瓦西股份有限公司 |
使用蒽醌类治疗过度增殖性疾病
|
|
US20060233810A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Yaolin Wang |
Methods and compositions for treating or preventing cancer
|
|
CA2503099A1
(en)
*
|
2005-04-18 |
2006-10-18 |
Kabushiki Kaisha Yakult Honsha |
Pharmaceutical compositions containing camptothecins
|
|
NZ562951A
(en)
*
|
2005-07-14 |
2011-09-30 |
Wellstat Biologics Corp |
Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
|
|
RU2447889C2
(ru)
*
|
2005-07-18 |
2012-04-20 |
Бипар Сайенсиз, Инк. |
Способ лечения рака (варианты)
|
|
TW200727900A
(en)
*
|
2005-07-27 |
2007-08-01 |
Yakult Honsha Kk |
Aqueous solution preparation containing camptothecins
|
|
US7608740B2
(en)
*
|
2005-08-03 |
2009-10-27 |
Avra Laboratories Pvt. Ltd |
Method of synthesizing key intermediates for the production of camptothecin derivatives
|
|
JP4994618B2
(ja)
*
|
2005-08-11 |
2012-08-08 |
学校法人北里研究所 |
Ts−1/カンプトテシン類による化学放射線療法
|
|
AU2006283174A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell-Matrix, Inc. |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
|
AU2006292328B2
(en)
|
2005-09-20 |
2012-12-20 |
Scinopharm Singapore Pte, Ltd. |
Novel crystal forms of irinotecan hydrochloride
|
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
|
EP1803725A1
(de)
*
|
2005-12-13 |
2007-07-04 |
W.C. Heraeus GmbH |
Verfahren zur Herstellung von Irinotecan
|
|
CN1982313B
(zh)
*
|
2005-12-13 |
2010-12-01 |
深圳市天和医药科技开发有限公司 |
10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
|
|
US20070208050A1
(en)
*
|
2006-02-24 |
2007-09-06 |
Palle Venkata Raghavendra Acha |
Process for preparing irinotecan
|
|
CN101033230B
(zh)
*
|
2006-03-10 |
2010-12-08 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及其应用
|
|
US8410045B2
(en)
*
|
2006-03-30 |
2013-04-02 |
Drais Pharmaceuticals, Inc. |
Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
|
|
PE20080695A1
(es)
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
|
CA2662337A1
(en)
|
2006-09-05 |
2008-03-13 |
Bipar Sciences, Inc. |
Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
|
|
CN101522609A
(zh)
|
2006-09-05 |
2009-09-02 |
彼帕科学公司 |
癌症的治疗
|
|
JP2010504318A
(ja)
*
|
2006-09-22 |
2010-02-12 |
ラボファーム インコーポレイテッド |
pH標的化薬剤送達のための組成物及び方法
|
|
EA200970353A1
(ru)
*
|
2006-10-06 |
2009-10-30 |
Такеда Фармасьютикал Компани Лимитед |
Комбинированное лекарственное средство
|
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
|
US20090062323A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched irinotecan
|
|
EP2211854A4
(de)
*
|
2007-10-19 |
2011-01-12 |
Bipar Sciences Inc |
Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp
|
|
US8329711B2
(en)
|
2007-10-23 |
2012-12-11 |
Msd K.K. |
Pyridone-substituted-dihydropyrazolopyrimidinone derivative
|
|
JP2011503111A
(ja)
|
2007-11-12 |
2011-01-27 |
バイパー サイエンシズ,インコーポレイティド |
Parp阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
|
|
EP2269072B1
(de)
*
|
2008-03-31 |
2017-08-23 |
Boston Medical Center Corporation |
Vorhersagemarker für topoisomerase-i-inhibitoren
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
TW201026715A
(en)
*
|
2008-12-23 |
2010-07-16 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
JP6104504B2
(ja)
*
|
2008-12-23 |
2017-03-29 |
ギリアド ファーマセット エルエルシー |
ヌクレオシド類似体
|
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
US8288396B2
(en)
|
2009-02-25 |
2012-10-16 |
Msdkk |
Pyrimidopyrimidoindazole derivative
|
|
EP2403339B1
(de)
|
2009-03-06 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Tumorkombinationstherapie mit einem akt-hemmer und anderen antumormitteln
|
|
BR112012012160B1
(pt)
|
2009-11-13 |
2022-04-26 |
Amgen, Inc. |
Material e métodos para tratar ou prevenir doenças associadas ao her-3
|
|
US8546573B2
(en)
|
2009-11-18 |
2013-10-01 |
Cadila Healthcare Limited |
Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
|
|
MX337393B
(es)
|
2009-11-18 |
2016-03-02 |
Nektar Therapeutics |
Forma salina de un conjugado de polímero-farmaco con multiples brazos.
|
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
|
CL2011000716A1
(es)
|
2010-03-31 |
2012-04-20 |
Gilead Pharmasset Llc |
Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
|
|
US8530444B2
(en)
*
|
2010-06-01 |
2013-09-10 |
Aposense Ltd. |
Pharmaceutical compounds
|
|
CA2815154A1
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
|
EP2655401B1
(de)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Hemmer der bindeinteraktion des epidermalen wachstumsfaktor-rezeptor-wärmeschock-proteins 90
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
WO2013093931A2
(en)
|
2011-09-19 |
2013-06-27 |
Sun Pharma Advanced Research Company Ltd. |
Novel prodrugs of phenolic drugs
|
|
JP6050822B2
(ja)
|
2011-10-03 |
2016-12-21 |
モレインクス,エービー |
ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
WO2014070233A1
(en)
|
2012-10-29 |
2014-05-08 |
Boston Medical Center Corporation |
Brca1 mutations as predictive markers for topoisomerase i inhibitors
|
|
CN103848840A
(zh)
*
|
2012-12-03 |
2014-06-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
喜树碱衍生物及其医药用途
|
|
CN103864810A
(zh)
*
|
2012-12-07 |
2014-06-18 |
天津科技大学 |
一种新颖的10-羟基喜树碱10位衍生物制备方法及其在抗肿瘤药物中的应用
|
|
AU2014245147B2
(en)
|
2013-03-27 |
2017-08-31 |
Les Laboratoires Servier |
Antitumor agent including low-dose irinotecan hydrochloride hydrate
|
|
TWI615145B
(zh)
|
2013-03-27 |
2018-02-21 |
Taiho Pharmaceutical Co Ltd |
含伊立替康鹽酸鹽水合物之抗腫瘤劑
|
|
US9907846B2
(en)
|
2013-04-01 |
2018-03-06 |
Mx Adjuvac Ab |
Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
|
|
EP2881396A1
(de)
*
|
2013-12-03 |
2015-06-10 |
Synbias Pharma AG |
Verfahren zur Synthese von Irinotecan
|
|
JP6704345B2
(ja)
*
|
2014-01-17 |
2020-06-03 |
オンコラル ファーマ エーピーエス |
癌治療のためのイリノテカンの固体経口剤形
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
EP3250611B1
(de)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car-t-zellen zur erkennung krebsspezifischer il 13r-alpha2
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
IL13Rα2結合剤及び癌治療におけるその使用
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
WO2016203352A2
(en)
*
|
2015-06-14 |
2016-12-22 |
Mohan M Alapati |
Compositions and methods for the treatment of cancer
|
|
WO2016203337A2
(en)
*
|
2015-06-14 |
2016-12-22 |
Mohan M Alapati |
Compositions and methods for the treatment of cancer
|
|
KR102293907B1
(ko)
|
2015-06-30 |
2021-08-26 |
한미약품 주식회사 |
이리노테칸 함유 경구용 고형제제 및 그 제조방법
|
|
PL3337467T3
(pl)
|
2015-08-20 |
2021-06-14 |
Ipsen Biopharm Ltd. |
Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
|
|
PL3337478T5
(pl)
|
2015-08-21 |
2026-05-04 |
Ipsen Biopharm Ltd. |
Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami
|
|
CA2995029C
(en)
|
2015-09-25 |
2022-10-25 |
Zy Therapeutics Inc. |
Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
|
|
AU2016340153B2
(en)
|
2015-10-16 |
2022-06-02 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
US9980953B2
(en)
*
|
2016-09-26 |
2018-05-29 |
Chong Kun Dang Pharmaceutical Corp. |
Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
|
|
EP3535026A1
(de)
|
2016-11-02 |
2019-09-11 |
Ipsen Biopharm Limited |
Behandlung von magenkrebs durch kombinationstherapien mit liposomalem irinotecan, oxaliplatin, 5-fluoruracil (und leucovorin)
|
|
CN108570057A
(zh)
*
|
2017-03-13 |
2018-09-25 |
烟台药物研究所 |
一种合成7-乙基-10-羟基喜树碱的方法
|
|
MA49849A
(fr)
|
2017-08-07 |
2020-06-17 |
Amgen Inc |
Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
|
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
|
TW202002952A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療胰臟癌之abbv-621與抗癌劑之組合
|
|
EP3669890A1
(de)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentöse nanopartikel mit impfstoffadjuvanswirkung
|
|
SG11202109986TA
(en)
|
2019-03-20 |
2021-10-28 |
Univ California |
Claudin-6 antibodies and drug conjugates
|
|
WO2020191344A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
CA3136496A1
(en)
|
2019-04-09 |
2020-10-15 |
The Board Of Trustees Of The University Of Illinois |
Drug adsorbed highly porous activated carbon for enhanced drug delivery
|
|
JP2022530241A
(ja)
|
2019-04-30 |
2022-06-28 |
インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス |
Cdk阻害剤と組み合わせたrank経路阻害剤
|
|
WO2020242720A1
(en)
|
2019-05-02 |
2020-12-03 |
University Of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
|
EP3986441A1
(de)
|
2019-06-24 |
2022-04-27 |
Amgen Inc. |
Inhibierung von sirp-gamma zur krebsbehandlung
|
|
CN111171077A
(zh)
*
|
2020-01-19 |
2020-05-19 |
上海交通大学医学院附属仁济医院 |
喜树碱衍生物及其制备方法和应用
|
|
US12521444B2
(en)
|
2021-02-25 |
2026-01-13 |
Fortvita Biologics Limited |
Anti-HER2 antibody-drug conjugates and uses thereof
|
|
KR20240113514A
(ko)
|
2021-11-30 |
2024-07-22 |
다이이찌 산쿄 가부시키가이샤 |
프로테아제 분해성 마스크 항체
|
|
KR20240141757A
(ko)
|
2022-02-09 |
2024-09-27 |
다이이찌 산쿄 가부시키가이샤 |
환경 응답성 마스킹 항체 및 그 이용
|